Articles from Aqtual, Inc.

Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics, today announced data that advance the understanding of why patients with rheumatoid arthritis (RA) respond differently to treatment and support the continued development of Aqtual’s RA treatment selection test, a blood-based biomarker test designed to help physicians choose among TNF inhibitors, JAK inhibitors, and abatacept for patients with RA before starting or switching treatment. Two posters being presented at the American College of Rheumatology (ACR) Convergence 2026, November 6–10 in Orlando, Florida, show that signals detected in blood reflect joint tissue biology associated with response to different RA medications, and that participants in Aqtual’s prospective PRIMA-102 study (NCT05936970) can be linked to real-world data to extend follow-up. Aqtual is also exhibiting at ACR at Booth #4119.

Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics, today announced the appointment of Daniil Kalyuzhny as Chief Financial Officer. Mr. Kalyuzhny joins Aqtual as the company enters its next stage of growth. Aqtual is advancing its first therapy-selection test toward clinical validation and commercialization while expanding the reach of its functional liquid biopsy platform across biopharmaceutical partnerships, co-development programs and strategic licensing opportunities.

Aqtual, Inc., a precision medicine company using its novel active chromatin cell-free DNA (cfDNA) platform to develop products for chronic diseases and oncology, today announced it has raised $31 million in Series B funding. Three new investors, including Bold Capital and Bold Longevity Growth Fund, joined previous investors Genoa Ventures, Manta Ray Ventures, and Yu Galaxy in participating in the oversubscribed round. Additional capital was also provided by a strategic investor in the diagnostics space, further strengthening Aqtual’s ability to advance the platform and its applications as it moves towards the commercialization of Aqtual’s first flagship product: a therapy response prediction test in rheumatoid arthritis (RA).

Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics for oncology and chronic disease, today announced new findings demonstrating its blood-based active chromatin cell-free DNA platform can simultaneously evaluate immune, stromal, and tumor-associated genomic biology from a single blood-based assay. These results highlight the potential of this approach to noninvasively monitoring dynamic changes in tumor microenvironment and emerging mechanisms of treatment resistance. The findings, led by investigators at UHN’s Princess Margaret Cancer Centre, were published in the peer-reviewed journal npj Precision Oncology[1] and will be extended with new longitudinal resistance analyses presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 - June 2 in Chicago.

Aqtual, Inc., a precision medicine company using its novel active chromatin cell-free DNA platform to develop products for chronic diseases and oncology, today announced the presentation of new data supporting its innovative blood-based test for rheumatoid arthritis (RA) therapy selection. Presented at the American College of Rheumatology (ACR) Convergence 2024, the data highlights significant clinical trial progress and reinforces the company's plans to commercialize the test in 2025.

Aqtual, Inc., a precision medicine company with a novel active chromatin cell-free DNA (cfDNAac) platform to develop products for chronic diseases and oncology, announced research in Communications Biology, a Nature portfolio journal. The research demonstrates the potential of Aqtual’s proprietary platform that evaluates gene regulation, epigenetics, and transcriptomics by analyzing previously unexplored cfDNA fragments found in blood, opening the door to new clinical applications in almost every major disease area.